TY - JOUR AU - El Gaamouch, Farida AU - Audrain, Mickael AU - Lin, Wei-Jye AU - Beckmann, Noam AU - Jiang, Cheng AU - Hariharan, Siddharth AU - Heeger, Peter S. AU - Schadt, Eric E. AU - Gandy, Sam AU - Ehrlich, Michelle E. AU - Salton, Stephen R. PY - 2020 DA - 2020/01/10 TI - VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice JO - Molecular Neurodegeneration SP - 4 VL - 15 IS - 1 AB - Multiomic studies by several groups in the NIH Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) identified VGF as a major driver of Alzheimer’s disease (AD), also finding that reduced VGF levels correlate with mean amyloid plaque density, Clinical Dementia Rating (CDR) and Braak scores. VGF-derived peptide TLQP-21 activates the complement C3a receptor-1 (C3aR1), predominantly expressed in the brain on microglia. However, it is unclear how mouse or human TLQP-21, which are not identical, modulate microglial function and/or AD progression. SN - 1750-1326 UR - https://doi.org/10.1186/s13024-020-0357-x DO - 10.1186/s13024-020-0357-x ID - El Gaamouch2020 ER -